USPTO serial 79052210
BASILEA PHARMACEUTICALS
Reviewed by CopyMark Law Group
Reg. 3602748Status 404
- Filing date
- Status date
- Registration date
- Apr 7, 2009
- Examiner
- EVANKO, PATRICIA MALESARDI
- Law office
- POST REGISTRATION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BASILEA PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Evan A. Raynes
Evan A. Raynes Symbus Law Group, LLC1425 K Street, N.W., Suite 350Washington, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical and veterinary products and preparations for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of allergy; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of anestesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; all of the aforesaid for prescription only | SECTION 71 - CANCELLED | — |
| 042 | Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Basilea Pharmaceutica Deutschland GmbH
- Other trademarks owned by Basilea Pharmaceuticals GmbH
- Other trademarks owned by Basilea Pharmaceutica AG
- Other trademarks owned by Basilea Pharmaceutica AG
- Other trademarks owned by Basilea Pharmaceutica AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named BASILEA PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 24, 2018 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Aug 24, 2018 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Feb 9, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 21, 2017 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 13, 2016 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jul 13, 2016 | INPC | INVALIDATION PROCESSED | — |
| Jul 13, 2016 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Nov 13, 2015 | C71T | CANCELLED SECTION 71 | — |
| Aug 13, 2015 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 28, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 28, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 13, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 24, 2009 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 24, 2009 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 8, 2009 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 28, 2009 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Apr 24, 2009 | PLGL | ASSIGNED TO PARALEGAL | — |
| Apr 24, 2009 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Apr 7, 2009 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 13, 2009 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 20, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 31, 2008 | NPUB | NOTICE OF PUBLICATION | — |
| Dec 16, 2008 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 11, 2008 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 10, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2008 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 2, 2008 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 2, 2008 | ALIE | ASSIGNED TO LIE | — |
| Nov 18, 2008 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 18, 2008 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2008 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 17, 2008 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 25, 2008 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Aug 28, 2008 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jun 6, 2008 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 21, 2008 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 21, 2008 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 21, 2008 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 20, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| May 9, 2008 | NWAP | NEW APPLICATION ENTERED | — |
| May 8, 2008 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |